Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT07069452
Recruiting Observational

Prognostic Value of Isolated and Combined Score Aspects in Acute Ischemic Stroke

NCT07069452 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier de Gonesse
Phase
Observational
Started
2025-04-15
Last updated
2025-07-16

Condition(s) studied

Stroke, IschemicThrombectomyThrombolytic TherapyBrain IschemiaPrognosisMagnetic Resonance ImagingOutcome Assessment (Health Care)

Study summary

This study, called TARGET-ASPECT, looks at patients who had a type of stroke called acute ischemic stroke and were treated with clot-busting medicine and a procedure to remove the clot. Even with these treatments, about half of patients don't fully recover. The study aims to see if certain brain imaging scores, especially when combined, can better predict how well patients will recover 90 days after their stroke and if their blood vessels reopen successfully. The study will include 152 patients and last about 9 months. The goal is to find easy and reliable tools that doctors can use to make better treatment decisions.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria : * Patients aged 18 years or older * Confirmed acute ischemic stroke on imaging * Treated with both thrombolysis and thrombectomy * Clinical follow-up data available at 90 days (mRS score) Exclusion Criteria : * Primary hemorrhagic stroke * Early death or loss to follow-up without evaluation * Poor-quality imaging that cannot be analyzed

Primary outcome measure(s)

  • Favorable functional outcome defined as a mRS score of 0 to 2 at 90 days — 90 days

Trial sites (1)

FacilityCityRegionStatus
Centre Hospitalier de Gonesse Gonesse France Recruiting

More Centre Hospitalier de Gonesse trials in France

Screening for Cognitive Disorders in Multiple Sclerosis Starting soon
High Risk of Death or Disability in Brain Hemorrhage: Role of Spot Sign and Secondary Markers Starting soon
Feasibility Study of a Relapse Investigation Questionnaire Administered by an MS Care Coordinator Nurse in Patients With Multiple Sclerosis Starting soon
Eligibility of Patients Referred to Emergency Departments by Their General Practitioners for Care in Walk-in Clinics: A Single-Center Study in Île-de-France Recruiting
Predictive Factors for Initial MMSE Score and Rapid Decline in Alzheimer's Disease Patients Starting soon

Other trials for the same condition

Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures Active, not recruiting
The Fourth Left Atrial Appendage Occlusion Study Recruiting
Kinetics of Urinary Excretion of Gadolinium Contrast Agents Used in MRI Examinations Recruiting
ENDOMETRIOSIS - MRI Recruiting
Effects of Atalante Exoskeleton on Gait Recovery in Non- or Poorly Ambulatory Patients With Hemiparesis in the Acute/Subacute Phase (Month 1 to 4) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07069452 on ClinicalTrials.gov ↗ ← All trials in France